Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma

References

• MoreauP, ZamagniE, MateosMV. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9(4):38. doi:10.1038/s41408-019-0200-130894516
   PubMed Web of Science ®Google Scholar
• GentileM, VignaE, RecchiaAG, MorabitoL, MartinoM, MorabitoF. Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients. Expert Opin Pharmacother. 2014;15(10):1315–1320. doi:10.1517/14656566.2014.91925724819321
   PubMed Web of Science ®Google Scholar
• GentileM, MorabitoF, MartinoM, et al. Chemotherapy-based regimens in multiple myeloma in 2020. Panminerva Med. 2021;63(1):7–12. doi:10.23736/S0031-0808.20.04145-232955186
   PubMed Web of Science ®Google Scholar
• GentileM, OffidaniM, VignaE. Ixazomib for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015;24(9):1287–1298. doi:10.1517/13543784.2015.1065250
   PubMed Web of Science ®Google Scholar
• GentileM, SpecchiaG, DerudasD, et al. Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica. 2021;106(1):291–294. doi:10.3324/haematol.2019.24151332107338
   PubMed Web of Science ®Google Scholar
• BottaC, MartinoEA, ConticelloC, et al. Treatment of lenalidomide exposed or refractory multiple myeloma: network meta-analysis of lenalidomide-sparing regimens. Front Oncol. 2021;11:643490. doi:10.3389/fonc.2021.64349033937048
   PubMed Web of Science ®Google Scholar
• MarkovicU, RomanoA, Del FabroV, et al. Daratumumab as single agent in relapsed/refractory myeloma patients: a retrospective real-life survey. Front Oncol. 2021;11:624405. doi:10.3389/fonc.2021.62440533763359
   PubMed Web of Science ®Google Scholar
• PalmieriS, RoccoS, VitaglianoO, et al. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol. 2020;99(12):2903–2909. doi:10.1007/s00277-020-04158-432583088
   PubMed Web of Science ®Google Scholar
• BringhenS, D’AgostinoM, ParisL, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica. 2020;105(7):1937–1947. doi:10.3324/haematol.2019.22640731582542
   PubMed Web of Science ®Google Scholar
• GentileM, MagarottoV, OffidaniM, et al. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: a comparison of two prospective trials. Am J Hematol. 2017;92(3):244–250. doi:10.1002/ajh.2462128006855
   PubMed Web of Science ®Google Scholar
• UccelloG, PetrungaroA, MazzoneC, et al. Pomalidomide in multiple myeloma. Expert Opin Pharmacother. 2017;18(2):133–137. doi:10.1080/14656566.2016.127497328002973
   PubMed Web of Science ®Google Scholar
• PozziS, GentileM, SacchiS, et al. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Leuk Lymphoma. 2017;58(3):552–559. doi:10.1080/10428194.2016.120574127442600
   PubMed Web of Science ®Google Scholar
• GentileM, MartinoM, RecchiaAG, VignaE, MorabitoL, MorabitoF. Sorafenib for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2016;6:1–7.
   Google Scholar
• GentileM, RecchiaAG, MazzoneC, et al. An old drug with a new future: bendamustine in multiple myeloma. Expert Opin Pharmacother. 2013;14(16):2263–2280. doi:10.1517/14656566.2013.83788524053161
   PubMed Web of Science ®Google Scholar
• GentileM, VignaE, RecchiaAG, et al. Bendamustine in multiple myeloma. Eur J Haematol. 2015;95(5):377–388. doi:10.1111/ejh.1260926085055
   PubMed Web of Science ®Google Scholar
• MorabitoF, BringhenS, LaroccaA, et al. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: a retrospective case-matched study. Am J Hematol. 2014;89(4):355–362. doi:10.1002/ajh.2364124273190
   PubMed Web of Science ®Google Scholar
• JasińskiM, BasakGW, JedrzejczakWW. Perspectives for the Use of CAR-T cells for the treatment of multiple myeloma. Front Immunol. 2021;12:632937. doi:10.3389/fimmu.2021.63293733717171
   PubMed Web of Science ®Google Scholar
• MaplesKT, JohnsonC, LonialS. Antibody treatment in multiple myeloma. Clin Adv Hematol Oncol. 2021;19(3):166–174.33739965
   PubMed Web of Science ®Google Scholar
• LassiterG, BergeronC, GuedryR, et al. Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects. Curr Oncol. 2021;28(1):640–660. doi:10.3390/curroncol2801006333494319
   PubMed Web of Science ®Google Scholar
• DevarakondaS, EfeberaY, SharmaN. Role of stem cell transplantation in multiple myeloma. Cancers (Basel). 2021;13(4):863. doi:10.3390/cancers1304086333670709
   PubMed Web of Science ®Google Scholar
• MartinoM, TripepiG, MessinaG, et al. A Phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transplant. 2016;51(9):1197–1203. doi:10.1038/bmt.2016.9427088375
   PubMed Web of Science ®Google Scholar
• MartinoM, RecchiaAG, FedeleR, et al. The role of tandem stem cell transplantation for multiple myeloma patients. Expert Opin Biol Ther. 2016;16(4):515–534. doi:10.1517/14712598.2016.113628526698133
   PubMed Web of Science ®Google Scholar
• MartinoM, OlivieriA, OffidaniM, et al. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs. 2013;22(5):619–634. doi:10.1517/13543784.2013.788643
   PubMed Web of Science ®Google Scholar
• MartinoM, RecchiaAG, ConsoleG, et al. Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma? Expert Opin Orph Drugs. 2017;5(11):875–887. doi:10.1080/21678707.2017.1387050
   Web of Science ®Google Scholar
• FurnerRL, BrownRK. L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep. 1980;64(4–5):559–574.7000345
   PubMedGoogle Scholar
• MustoP, D’AuriaF. Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Investig Drugs. 2007;16(9):1467–1487. doi:10.1517/13543784.16.9.1467
   PubMed Web of Science ®Google Scholar
• MartinoM, PostorinoM, GalloGA, et al. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Clin Lymphoma Myeloma Leuk. 2014;14(2):148–154. doi:10.1016/j.clml.2013.11.00924417912
   PubMed Web of Science ®Google Scholar
• SpornJR, McLntyreOR. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin Oncol. 1986;13(3):318–325.3532330
   PubMed Web of Science ®Google Scholar
• MateosMV, DimopoulosMA, CavoM, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528. doi:10.1056/NEJMoa171467829231133
   PubMed Web of Science ®Google Scholar
• PalumboA, BringhenS, RossiD, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101–5109. doi:10.1200/JCO.2010.29.821620940200
   PubMed Web of Science ®Google Scholar
• McElwainTJ, PowlesRL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822–824. doi:10.1016/S0140-6736(83)90739-06137651
   PubMed Web of Science ®Google Scholar
• KazandjianD, MoCC, LandgrenO, RichardsonPG. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol. 2020;191(5):692–703. doi:10.1111/bjh.1676432501533
   PubMed Web of Science ®Google Scholar
• GullboJ, WickströmM, TullbergM, et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target. 2003;11(6):355–363. doi:10.1080/1061186031000164714014668056
   PubMed Web of Science ®Google Scholar
• GullboJ, DharS, LuthmanK, et al. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan. Anticancer Drugs. 2003;14(8):617–624. doi:10.1097/00001813-200309000-0000614501383
   PubMed Web of Science ®Google Scholar
• GullboJ, LindhagenE, Bashir-HassanS, et al. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drugs. 2004;22(4):411–420. doi:10.1023/B:DRUG.0000036683.10945.bb15292711
   PubMed Web of Science ®Google Scholar
• WickstromM, ViktorssonK, LundholmL, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281–1290. doi:10.1016/j.bcp.2009.12.02220067771
   PubMed Web of Science ®Google Scholar
• WickstromM, NygrenP, LarssonR, et al. Melflufen—A peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017;8(39):66641–66655. doi:10.18632/oncotarget.1842029029544
   PubMedGoogle Scholar
• FDA approves Oncopeptides’ PEPAXTO® (melphalan flufenamide) for patients with relapsed or refractory multiple myeloma. News release. Oncopeptides, AB; 2 26, 2021. Accessed February 26, 2021.
   Google Scholar
• De BarbieriA Peptichemio: a synthesis of pharmacological, morpho- logical, biochemical and biomolecular investigations. In: Proceedings from the Symposium on Peptichemio, Milan, Italy, 1972.
   Google Scholar
• HanssonJ, LewensohnR, RingborgU. Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells. Anticancer Res. 1991;11(5):1725–1730.1768043
   PubMed Web of Science ®Google Scholar
• LewensohnR, EhrssonH, HanssonJ, RingborgU. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Pepti- chemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines. Anticancer Res. 1991;11(1):321–324.2018366
   PubMed Web of Science ®Google Scholar
• WickströmM, HaglundC, LindmanH, NygrenP, LarssonR, GullboJ. The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro. Invest New Drugs. 2008;26(3):195‐204. doi:10.1007/s10637-007-9092-1
   Web of Science ®Google Scholar
• WickstromM, LarssonR, NygrenP, GullboJ. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011;102(3):501–508. doi:10.1111/j.1349-7006.2010.01826.x21205077
   PubMed Web of Science ®Google Scholar
• Mina-OsorioP. The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med. 2008;14(8):361–371. doi:10.1016/j.molmed.2008.06.00318603472
   PubMed Web of Science ®Google Scholar
• ChauhanD, RayA, ViktorssonK, et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013;19(11):3019–3031. doi:10.1158/1078-0432.CCR-12-375223584492
   PubMed Web of Science ®Google Scholar
• MiettinenJJ, KumariR, TraustadottirGA, et al. Aminopeptidase expression in multiple myeloma associates with disease progression and sensitivity to melflufen. Cancers (Basel). 2021;13(7):1527. doi:10.3390/cancers1307152733810334
   PubMed Web of Science ®Google Scholar
• KumariR, MajumderMM, LievonenJ, et al. Prognostic significance of esterase gene expression in multiple myeloma. Br J Cancer. 2021;124(8):1428–1436. doi:10.1038/s41416-020-01237-133531688
   PubMed Web of Science ®Google Scholar
• GullboJ, TullbergM, VabenoJ, et al. Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives. Oncol Res. 2003;14(3):113–132. doi:10.3727/00000000377101307114760861
   PubMed Web of Science ®Google Scholar
• MooreHE, DavenportEL, SmithEM, et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther. 2009;8(4):762–770. doi:10.1158/1535-7163.MCT-08-073519372548
   PubMed Web of Science ®Google Scholar
• BerglundÅ, UllénA, LisyanskayaA, et al. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. Invest New Drugs. 2015;33(6):1232–1241. doi:10.1007/s10637-015-0299-226553306
   PubMed Web of Science ®Google Scholar
• GullboJ. Preclinical development of new alkylating oligopeptides for cancer therapy. Medical Sciences, Dept of Clinical PharmacologyUppsala: Uppsala University; 2003.
   Google Scholar
• WickstromM, JohnsenJI, PonthanF, et al. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther. 2007;6(9):2409–2417. doi:10.1158/1535-7163.MCT-07-015617876040
   PubMed Web of Science ®Google Scholar
• ByrgazovK, AndersonC, SalzerB, et al. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. Ther Adv Med Oncol. 2020;12:1758835920937891. doi:10.1177/175883592093789132774473
   PubMed Web of Science ®Google Scholar
• WangS, XieH, Xing WeiX, et al. Relation between the expression of aminopeptidase N (APN)/CD13 and the clinical significance in osteosarcomas. Int J Clin Exp Med. 2016;9:22034–22040.
   Web of Science ®Google Scholar
• FalcoP, BringhenS, AvontoI, et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther. 2007;7(7):945–957. doi:10.1586/14737140.7.7.94517627453
   PubMed Web of Science ®Google Scholar
• HazlehurstLA, EnkemannSA, BeamCA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003;63(22):7900–7906.14633719
   PubMed Web of Science ®Google Scholar
• JonesRB. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res. 2002;112:305–322.12481722
   PubMedGoogle Scholar
• McHughPJ, SpanswickVJ, HartleyJA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001;2(8):483–490. doi:10.1016/S1470-2045(01)00454-511905724
   PubMed Web of Science ®Google Scholar
• SpanswickVJ, CraddockC, SekharM, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood. 2002;100(1):224–229. doi:10.1182/blood.V100.1.22412070031
   PubMed Web of Science ®Google Scholar
• RayA, DasDS, SongY, et al. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016;174(3):397–409. doi:10.1111/bjh.1406527098276
   PubMed Web of Science ®Google Scholar
• RichardsonPG, BringhenS, VoorheesP, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study. Lancet Haematol. 2020;7(5):e395–e407. doi:10.1016/S2352-3026(20)30044-232213344
   PubMed Web of Science ®Google Scholar
• BringhenS, VoorheesPM, PlesnerT, et al. Melflufen plus dexamethasone in relapsed/ refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. Br J Haematol. 2021;193(6):1105–1109. doi:10.1111/bjh.1730233403663
   PubMed Web of Science ®Google Scholar
• RichardsonPG, OriolA, LaroccaA, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39(7):757–767. doi:10.1200/JCO.20.0225933296242
   PubMed Web of Science ®Google Scholar
• OcioEM, EfeberaYA, HajekR, et al. ANCHOR (OP-104): melflufen plus dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/ Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety. Blood. 2020;136(suppl 2):abs 417. doi:10.1182/blood-2020-135991
   Web of Science ®Google Scholar
• SchjesvoldF, RobakP, PourL, AschanJ, SonneveldP. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future Oncol. 2020;16(11):631–641. doi:10.2217/fon-2020-002432141766
   PubMed Web of Science ®Google Scholar
• NIH Clinical Trials. A PK study of melphalan during treatment with Melphalan Flufenamide (Melflufen) and Dex in RRMM pat with impaired renal function. https://clinicaltrials.gov/ct2/show/NCT03639610. Accessed 625, 2021.
   Google Scholar
• DimopoulosMA, SonneveldP, LeungN, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557. doi:10.1200/JCO.2015.65.004426976420
   PubMed Web of Science ®Google Scholar
• MateosMV, OcioEM, SonneveldP, et al. LIGHTHOUSE (OP-108): a phase 3 study of melflufen in combination with daratumumab versus daratumumab in patients with relapsed/refractory multiple myeloma. EHA Congress; 2020; abs PB2018.
   Google Scholar
• San-MiguelJF, HungriaVT, YoonSS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206. doi:10.1016/S1470-2045(14)70440-125242045
   PubMed Web of Science ®Google Scholar
• LonialS, LeeHC, BadrosA, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221. doi:10.1016/S1470-2045(19)30788-031859245
   PubMed Web of Science ®Google Scholar